Zuellig Pharma, a leading healthcare services provider in Asia, and Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has applied for emergency use authorization for the Moderna COVID-19 vaccine with the Food and Drug Administration.
The application for EUA was filed by Zuellig Pharma Corporation.
“We have filed the EUA application with all required documents,” said Raymund Azurin, Senior Vice President for Government Affairs and Sustainability of Zuellig Pharma Asia Pacific.
“We look forward to the FDA’s decision as we help bring the Moderna vaccine to the country,” Azurin said.
Vaccine czar Carlito Galvez Jr. said the EUA filing brings the Philippines a step closer to its goal of vaccinating 70 million of our adult population this year.
“We welcome the EUA application of Moderna, following the signing of the tripartite agreement with the private sector. We know the FDA Philippines will give it urgent attention,” he said.
“Today’s submission is another important step in the global fight against COVID-19. We thank the Government of the Philippines for their collaboration to bring the COVID-19 Vaccine Moderna to the Philippines,” said Stéphane Bancel, Chief Executive Officer of Moderna.
“We remain committed to making our vaccine available on every continent to help end this global pandemic,” Bancel added.
Moderna’s mRNA vaccine against COVID-19 has been approved for emergency use in the United States, Canada, Israel, the European Union, the United Kingdom, Switzerland, Qatar, Singapore, and Taiwan.
